Researcher.Life Logo

Infectious Diseases and Therapy : Impact Factor & More

eISSN: 2193-6382pISSN: 2193-8229
JournalOpen Access

Key Metrics

CiteScore
6.1
Eigenfactor
0.001 - 0.005
H-Index
39
Impact Factor
5 - 10
SJR
Q1Infectious Diseases
SNIP
1.81
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on Infectious Diseases and Therapy

Infectious Diseases and Therapy Journal Specifications

Overview
Publisher SPRINGER LONDON LTD
Language English
Frequency Quarterly
Article Processing ChargesGBP 4700 | USD 6850 | EUR 5500
Publication Time6
Editorial Review ProcessAnonymous peer review
General Details
LanguageEnglish
FrequencyQuarterly
Publication Start Year2012
Publisher URLVisit website
Website URLVisit website
Publication Details
PlagiarismVisit website
Publication Time 6
Editorial Review Detail
Editorial TeamVisit website
Review ProcessAnonymous peer review
Review UrlVisit website
Information for authors
Author instructionsVisit website
Copyright DetailsVisit website
Deposit PolicySherpa/Romeo
License typeCC BY-NC
OA statementVisit website
View less

Planning to publish in Infectious Diseases and Therapy ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Infectious Diseases and Therapy

Evaluating the Effectiveness of 2024-2025 Seasonal mRNA-1273 Vaccination Against COVID-19-Related Hospitalizations and Medically Attended COVID-19 Among Adults Aged≥18years in the United States: An Observational Matched Cohort Study.
  • 10 Jan 2026
  • Infectious diseases and therapy
Characteristics of Haemophilus influenzae Isolates Responsible for Invasive Infections in Poland in 2018-2023.
  • 8 Jan 2026
  • Infectious diseases and therapy
Clinical Phenotypes of Critically Ill Patients with COVID-19 Infected with Omicron: A Nationwide Prospective Cohort Study.
  • 6 Jan 2026
  • Infectious diseases and therapy
Comparative Diagnostic Performance of the 36-Minute STANDARD M10 Fast Assay for Molecular Diagnosis of SARS-CoV-2, InfluenzaA and B, and Respiratory Syncytial Virus in Near-Patient Settings.
  • 3 Jan 2026
  • Infectious diseases and therapy
Continuous Infusion of Aztreonam-Avibactam After High Loading Dose for an Infection Caused by an OXA-48- and NDM-1-Co-producing ST147 Klebsiella pneumoniae.
  • 2 Jan 2026
  • Infectious diseases and therapy
Understanding the Epidemiology and Contributing Factors of Post-COVID-19 Pertussis Outbreaks: A Narrative Review.
  • 1 Jan 2026
  • Infectious diseases and therapy
Evaluating the Effectiveness of 2024-2025 Seasonal mRNA-1273 Vaccination Against COVID-19-Related Hospitalizations and Medically Attended COVID-19 Among Adults Aged≥18years in the United States: An Observational Matched Cohort Study.
  • 10 Jan 2026
  • Infectious diseases and therapy
Characteristics of Haemophilus influenzae Isolates Responsible for Invasive Infections in Poland in 2018-2023.
  • 8 Jan 2026
  • Infectious diseases and therapy
Clinical Phenotypes of Critically Ill Patients with COVID-19 Infected with Omicron: A Nationwide Prospective Cohort Study.
  • 6 Jan 2026
  • Infectious diseases and therapy
Comparative Diagnostic Performance of the 36-Minute STANDARD M10 Fast Assay for Molecular Diagnosis of SARS-CoV-2, InfluenzaA and B, and Respiratory Syncytial Virus in Near-Patient Settings.
  • 3 Jan 2026
  • Infectious diseases and therapy
Continuous Infusion of Aztreonam-Avibactam After High Loading Dose for an Infection Caused by an OXA-48- and NDM-1-Co-producing ST147 Klebsiella pneumoniae.
  • 2 Jan 2026
  • Infectious diseases and therapy
Understanding the Epidemiology and Contributing Factors of Post-COVID-19 Pertussis Outbreaks: A Narrative Review.
  • 1 Jan 2026
  • Infectious diseases and therapy

FAQs on Infectious Diseases and Therapy